Stryker/$SYK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Stryker
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
- Ticker
- $SYK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 56,000
- Headquarters
- Portage, United States
- Website
- www.stryker.com
Stryker Metrics
BasicAdvanced
$118B
31.82
$9.65
0.77
$3.48
1.15%
Price and volume
Market cap
$118B
Beta
0.77
52-week high
$389.33
52-week low
$267.00
Average daily volume
2.7M
Dividend rate
$3.48
Financial strength
Current ratio
2.157
Quick ratio
1.08
Long term debt to equity
0.592
Total debt to equity
0.592
Dividend payout ratio (TTM)
35.32%
Interest coverage (TTM)
10.26%
Profitability
EBITDA (TTM)
7,376
Gross margin (TTM)
65.59%
Net profit margin (TTM)
14.43%
Operating margin (TTM)
23.82%
Effective tax rate (TTM)
27.56%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
8.16%
Return on equity (TTM)
16.51%
Valuation
Price to earnings (TTM)
31.824
Price to revenue (TTM)
4.55
Price to book
4.91
Price to tangible book (TTM)
-88.02
Price to free cash flow (TTM)
25
Free cash flow yield (TTM)
4.00%
Free cash flow per share (TTM)
12.283
Dividend yield (TTM)
1.13%
Forward dividend yield
1.15%
Growth
Revenue change (TTM)
8.48%
Earnings per share change (TTM)
27.79%
3-year revenue growth (CAGR)
9.92%
10-year revenue growth (CAGR)
9.45%
3-year earnings per share growth (CAGR)
10.87%
10-year earnings per share growth (CAGR)
8.57%
3-year dividend per share growth (CAGR)
5.72%
10-year dividend per share growth (CAGR)
8.89%
What the Analysts think about Stryker
Analyst ratings (Buy, Hold, Sell) for Stryker stock.
Analyst projections of the future price of Stryker stock.
Bulls say / Bears say
Second-quarter sales rose 9.4%, with organic growth of 9.0%, and adjusted operating margin widened by 170 basis points to 27.4%. That combination suggests Stryker is converting strong procedure demand into improved profitability. (GlobeNewswire)
The July US launch of Mako RPS extends Stryker’s robotics offer to surgeons who prefer a handheld workflow, potentially opening a new customer segment. The wider Mako platform has already supported more than 2.5 million procedures across 47 countries. (Stryker)
Stryker reported elevated demand and a strong order backlog for capital equipment as it recovered from the cyber disruption. Converting that backlog into deliveries could support near-term sales growth. (The Motley Fool)
A manufacturing problem in peripheral vascular continued to restrict supply, and management said in September it was likely to persist into the fourth quarter. The delay risks lost sales and could weaken confidence in the company’s recovery timetable. (Stock Analysis, Investing.com)
The cyber incident disrupted manufacturing and left Stryker facing idle-capacity and remediation costs through 2026. Those expenses could limit how much of its sales growth reaches earnings. (The Motley Fool)
The FDA classified Stryker’s InZone Detachment System recall as Class II after devices were found to risk premature battery drain and failure to detach a coil as intended. Further quality problems could bring added costs and weigh on customer confidence. (U.S. Food and Drug Administration)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Stryker Financial Performance
Revenues and expenses
Stryker Earnings Performance
Company profitability
Upcoming events
Stryker News
AllArticlesVideos
Funds containing Stryker
AllUSDEURGBP
Fund name | Fund size | $SYK weighting |
|---|---|---|
iShares AI Adopters and Applications£AIAA | $188M | 1.78% |
iShares AI Adopters and Applications€AIAA | $188M | 1.78% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.61% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.61% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 1.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.